Blog
RSS FeedPosted by Michael Wonder on 22 Nov 2016
Allergan announces receipt of additional Health Canada approval for Fibristal
21 November 2016 - Allergan announced that it has received an additional approval from Health Canada for Fibristal (ulipristal acetate, 5 ...
Posted by Michael Wonder on 15 Nov 2016
Once-daily anticoagulant Lixiana (edoxaban tosylate) approved in Canada for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrent deep-vein thrombosis and pulmonary embolism
9 November 2016 - Servier Canada announced today that Lixiana (edoxaban tosylate) has been approved by Health Canada for the two ...
Posted by Michael Wonder on 02 Nov 2016
Health Canada approves Alecensaro - a targeted oral treatment - for patients with aggressive and rare form of lung cancer
31 October 2016 - Early data suggests Alencensaro also shows strong efficacy in treating the spread of lung cancer to ...
Posted by Michael Wonder on 26 Oct 2016
First and only medication approved in Canada for the treatment of binge eating disorder
25 October 2016 - Vyvanse (lisdexamphetamine dimesylate) now indicated for the treatment of moderate to severe binge eating disorder ...
Posted by Michael Wonder on 12 Oct 2016
Health Canada greenlights MendeliKABS for the commercialisation of PrMDK-nitisinone
11 October 2016 - MendeliKABS is proud to announce that Health Canada has approved MDK-Nitisinone medication for the treatment of hereditary ...
Posted by Michael Wonder on 06 Oct 2016
AbbVie's new oral therapy Venclexta now available for Canadians with a difficult-to-treat blood cancer
5 October 2016 - Health Canada's approval of Venclexta reinforces AbbVie's growing position in hematologic oncology. ...
Posted by Michael Wonder on 13 Sep 2016
New biosimilar can offer an effective and lower cost treatment option for Canadians living with rheumatoid arthritis and ankylosing spondylitis
12 September 2016 - Broader adoption of preferential listing for biosimilars as part of private drug programs can also create ...
Posted by Michael Wonder on 24 Aug 2016
Teva Canada Innovation announces approval of three-times-a-week Copaxone 40mg/mL by Health Canada
23 August 2016 - Teva Canada Innovation announced today that Health Canada has approved three-times-a-week Copaxone (glatiramer acetate) 40 mg/mL injection. ...
Posted by Michael Wonder on 12 Aug 2016
Health Canada approves new indication for Jardiance (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease
11 August 2016 - Approval based on cardiovascular outcome clinical trial EMPA-REG OUTCOME, which demonstrated empagliflozin significantly reduced the incidence of ...
Posted by Michael Wonder on 09 Aug 2016
New treatment option for Canadians living with multiple myeloma
8 August 2016 - Takeda Canada receives approval for Ninlaro (ixazomib) - the first and only oral proteasome inhibitor providing a ...
Posted by Michael Wonder on 22 Jul 2016
Pediapharm receives Health Canada approval for rupatadine
21 July 2016 - Pediapharm is very pleased to announce Health Canada's approval of rupatadine fumarate (10 mg tablets and 1 ...
Posted by Michael Wonder on 21 Jul 2016
Health Canada approves Invokamet for the treatment of adults with type 2 diabetes mellitus
20 July 2016 - Janssen announced today that Invokamet, a twice daily fixed-dose therapy combining Invokana (canagliflozin) and metformin hydrochloride into ...
Posted by Michael Wonder on 15 Jul 2016
Gilead receives approval in Canada for Epclusa (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C
14 July 2016 - Two week treatment with Epclusa provides high cure rates for all six hepatitis C genotypes. ...
Posted by Michael Wonder on 12 Jul 2016
Tagrisso (osimertinib mesylate) approved by Health Canada as treatment for patients with locally advanced or metastatic EGFR T790M mutation-positive non-small cell lung cancer
1 July 2016 - A result of one of the fastest development programs from start of clinical trials to regulatory approval. ...
Posted by Michael Wonder on 30 Jun 2016
Darzalex (daratumumab) approved by Health Canada as the first human anti-CD38 monoclonal antibody for the treatment of multiple myeloma
30 June 2016 - Darzalex is a new therapy providing an important option for multiple myeloma patients who have received three ...